Bio-Rad and Seegene Enter into Partnership for Molecular Diagnostic Testing Products

By LabMedica International staff writers
Posted on 02 Jul 2021

Bio-Rad Laboratories (Hercules, CA, USA) and Seegene, Inc. (Seoul, Korea) have entered into a partnership for the clinical development and commercialization of infectious disease molecular diagnostic products.

Under the terms of the agreement, Seegene will provide diagnostic tests for use on Bio-Rad’s CFX96 Dx Real-Time PCR System for U.S. markets pending clinical development and clearance from the US Food & Drug Administration (FDA). Seegene assays offer multiplex real-time PCR detection and differentiation, with high sensitivity and specificity of up to seven targets in a single reaction. The assays deliver results in approximately four hours.

Illustration

“We look forward to working with Seegene to provide needed diagnostic testing products to US markets,” said Dara Wright, Bio-Rad EVP and President, Clinical Diagnostics. “Seegene’s unique assay design, chemistries, and high-level multiplexing can detect multiple infectious disease targets simultaneously, making the assays well-suited for syndromic testing.”

Related Links:
Bio-Rad Laboratories
Seegene, Inc.